摘要
靶向药物的耐药问题在黑色素瘤的治疗中逐渐显现,目前已知的药物耐药机制包括丝裂原激活蛋白激酶（MAPK）通路再活化、MAPK旁路途径的激活、肿瘤微环境的影响、微小RNA的异常表达等.通过黑色素瘤靶向药物的联合应用、免疫联合治疗等策略可延缓耐药性的发生,延长患者的生存期.
Drug resistance of targeted therapy gradually emerges in the treatment of melanoma.Currently known mechanisms of drug resistance include reactivation of mitogen-activated protein kinase （MAPK） pathway,activation of MAPK alternative pathway,effects of tumor microenvironment,and abnormal expression of microRNA.Through the combination of targeted drugs,immunological combination therapy and other strategies can delay the occurrence of drug resistance,thereby prolonging the survival of patients.
作者
金兰
康晓静
Jin Lan,Kang Xiaojing(Postgraduate School of Xinfiang Medical University; Department of Dermatology and Venereology,People＇s Hospital of Xinfiang Uygur Autonomous Region, Urumqi 830001, China)
出处
《国际肿瘤学杂志》
CAS
2018年第7期444-448,共5页
Journal of International Oncology
基金
新疆维吾尔自治区自然科学基金（2016D01C101）
关键词
黑色素瘤
抗药性
肿瘤
靶向治疗
Melanoma
Drug resistance
neoplasm
Targeted therapy
